To assess the effects of a prostate cancer (PCa) clinical pathway on the implementation of evidence-based strategies for the management of androgen deprivation therapy (ADT)-induced side effects.
Introduction
Androgen deprivation therapy (ADT) is one of the cornerstones in the treatment of locally advanced and metastatic prostate cancer (PCa) [1] . Despite the survival improvement [1] , ADT also negatively influences bone, metabolic, cardiovascular, sexual and cognitive health as well as body composition, fatigue and vasomotor flushing [2] [3] [4] [5] . These side effects are detrimental for the patient's health and quality of life [4, [6] [7] [8] , therefore, it is imperative to mitigate them through the introduction of treatments aimed at reducing them. Evidence-based guidelines have been drawn up to reduce the impact of ADT-induced side effects [5, 7] , but a European study showed that these guidelines are not sufficiently applied in clinical routine [9] . Clinical pathways are often implemented to optimize adherence to guidelines [10] and are widely used to structure and standardize evidence-based care processes and improve quality of care and patient outcomes [11] for a broad variety of patient groups, such as those who have undergone orthopaedic surgery [12] , or who have experienced stroke [13] and heart failure [14] . Clinical pathways are also incorporated in different cancer care treatments [15, 16] , but, to our knowledge have not yet been studied for the management of ADT-induced side effects in patients with PCa. The aim of the present study was to assess the effects of the implementation of a clinical pathway on evidence-based strategies to manage ADT-induced side effects by comparing the applied strategies before and after pathway implementation.
Patients and Methods
This study was approved by the Ethics Committee of the University Hospital of Ghent (EC UZG 2016/0048). To improve implementation of evidence-based strategies for ADT-induced side effects, and thus quality of care and patient outcomes, a clinical pathway was introduced according to the definition of the European Pathway Association adapted from Vanhaecht et al. [11] 'A complex intervention for the mutual decision making and organization of care processes for a well-defined group of patients during a well-defined period'. The clinical pathway was based on evidence-based guidelines to manage ADT-induced side effects [5, 7, 17] and is shown in Fig. 1 .
Clinical Pathway Intervention
The clinical pathway was implemented at hospital level in the care process from January 2015. Development of the clinical pathway was based on the seven-phase framework for the development, implementation and evaluation of a clinical pathway described by Vanhaecht et al. [18] . A multidisciplinary team (radiation oncologist, urologist, psychologist, dietician, oncology nurse, physical therapist, social worker and pathway facilitator) for pathway development, implementation and evaluation was created, with one central clinical pathway coordinator (e.g. pathway facilitator). The multidisciplinary team analysed daily practices, current deficits in the care process (e.g. lack of time to promote preventive strategies and lack of resources), evidence-based guidelines for the management of ADTinduced side effects and other potential transferrable existing pathways. As a result, a pathway protocol was developed, as well as an implementation plan. The pathway is aimed at all patients with PCa receiving ADT for a time period >6 months (e.g. patients with locally advanced and advanced metastatic PCa). The pathway consists of several risk screening assessments and preventive strategies (Fig. 1) . The bone risk screening consists of a bone mineral density (BMD) and/or the WHO fracture risk assessment tool at the onset of ADT. Cardiometabolic screening consists of medical history assessment (cardiac history, hypertension, diabetes and hypercholesterolaemia), biomarker screening (fasting glucose and lipid profile), blood pressure screening and anthropometric measurements (weight, length, skinfold thickness, waist-hip circumference and body fat percentage). For the preventive strategies, the following components were offered: a supervised exercise programme (aerobic, resistance and flexibility training, twice per week for 1.5 h per session and active lifestyle advice); referral to a dietician (offering healthy diet advice and advice on reducing alcohol intake); an appointment with a psychologist (for psycho-education) and advice on adequate intake or supplementation of calcium and vitamin D.
In practice, the radiation oncologist and urologist refer the patients to the pathway coordinator, who discusses the pathway with the patients and significant others. The pathway coordinator provides follow-up appointments for the screening assessments and preventive strategies.
Finally, the pathway undergoes a continuous evaluation process at both patient and healthcare professional level.
Study Participants
To be eligible for the present study, patients had to be treated (or planned to be) with ADT LHRH antagonists or agonists) for >6 months. Patients with a Karnofsky performance score of ≤50 were excluded. All patients receiving treatment or follow-up at the University Hospital of Ghent in 2014 or 2015 were assessed for eligibility. Patients receiving ADT during the year 2014 were allocated to the control group (before pathway implementation) and patients receiving ADT in 2015 to the intervention group (after pathway implementation). The aim of the pathway was that all patients with PCa receiving ADT or with ADT planned for >6 months should be included in it. In practice, three scenarios were possible: (i) patients were not referred to the pathway; (ii) patients were referred to the pathway, but refused inclusion; and (iii) patients were referred to and included in the pathway. Patients in the intervention group, therefore, are a combination of those three scenarios. The three scenarios were combined to obtain a realistic representation of daily clinical practice.
Data Collection and Measurements
Data were abstracted from the electronic health records of all eligible patients with PCa. Two researchers (R.B. and E.R.) independently screened all electronic health records for eligibility. After screening for eligibility, two researchers (R.B. and I.V.D.C.) each extracted the data from half of the records. Data information (e.g. risk assessments) was collected at the onset of ADT (within a 3-month time frame). All relevant clinician notes were searched. Records of a random sample of 5% of patients were screened by a third researcher (S.E.) in order to maximize inter-rater agreement.
All measurements were positively scored when found <3 months after onset of ADT. Bone risk screening was scored when an order for the screening was made or when a BMD or FRAX score was present. The presence of medical history assessment was administered when presence or absence of a diagnosis of hypertension, diabetes or cardiac history of hypercholesterolaemia was described. The presence of biomarkers, blood pressure and anthropometric measurements was recorded positively when an order had been made or the results of the test were found within the time period of 3 months. Vitamin D and calcium supplementation or adequate intake was scored when a prescription by a physician was found in the health records, adequate intake was administered or supplementation was seen in the medication record. Exercise was defined as 'physical activity that is planned, structured, repetitive and purposive in the sense that improvement or maintenance of one or more components of physical fitness is an objective' [19] . Exercise advice was scored as sufficient when the supervised hospital-based exercise programme or another equivalent exercise programme was offered or when an individual-adjusted exercise scheme was provided to the patient. Diet advice was considered positively administered when patients were referred to a dietician or patients were already in follow-up with a dietician. Referral to a psychologist, already in follow-up with a psychologist (or psychiatrist) or participation in an interactive psychosocial group session in the hospital was positively scored for psycho-education.
Data Analyses
To assess the effects of the clinical pathway, evidence-based strategies [5, 7] were translated to dichotomous indicators, Figure 2 shows the implementation of ADT evidence-based strategies for both groups. All risk screening assessments (bone, metabolic, cardiac assessment and lipid profile) were performed more often in the pathway group (58%, 46%, 61% and 52%, respectively), than in the control group (10%, 4%, 16% and 34%, respectively), except for glucose profile (P = 0.004) and haemoglobin (P = 0.975; Fig. 2A ). Medical history was more often documented in the pathway group for the following comorbidities: diabetes (79% intervention group vs 52% control group); hypertension (83% vs 62%); cardiac history (74% vs 33%); and hypercholesterolaemia (73% vs 34%; P < 0.001; Fig. 2B ). All preventive strategies (exercise advice, diet advice, psycho-education and vitamin D and calcium supplementation) were significantly (P < 0.001) more often provided in the pathway group (62%, 58%, 46% and 67%, respectively) compared with the control group (11%, 10%, 13% and 29%, respectively; Fig. 2C ). 
Comorbidity Risk Factors: Intervention Group
In 2015, 61% of patients were referred to the clinical pathway (52% were included in the pathway and 9% of the patients refused inclusion) and 39% of patients were not referred to the pathway. Table 2 shows the comorbidity risk factors identified in the intervention group. The control group was excluded from Table 2 because of the low number of available risk assessments and therefore the high possibility of the group being non-representative.
Within the intervention group, 53% of the patients were overweight and 20% were obese. A diagnosis of hypertension was recorded in 57% of the intervention group and 49% had hypercholesterolaemia. Fasting triglyceride levels were borderline to high in 26% of the patients, 38% had a borderline to high cholesterol level and almost 23% had a borderline to very high LDL cholesterol. Fasting glucose (excluding patients with known diabetes) was borderline high in 28% and high in 15% of the patients, and 19% had a diagnosis of diabetes in the intervention group. Of the patients with a medical history documented in the pathway group, 47% had a positive cardiac history. A lower BMD was found in 41% of the patients undergoing a BMD test, 29% were diagnosed with osteopenia and 12% with osteoporosis. After providing exercise and diet advice, 64% of the patients met the physical activity recommendations (resistance, cardiac and flexibility training) and improved nutrition intake. In the pathway group, 46% of the patients received psycho-education compared with 13% in the control group (P < 0.001).
Discussion
Implementation of evidence-based strategies for ADT-induced side effects in clinical practice is insufficient [9] . In 2015, we implemented a clinical pathway to improve the adherence to evidence-based guidelines. The present study shows that the implementation of a pathway increases uptake of evidencebased strategies to mitigate ADT-induced side effects in clinical routine. The implementation of a clinical pathway for patients with PCa receiving ADT can effectively improve quality of care. Both risk screening strategies and preventive strategies were significantly more often applied after implementation of the pathway, except for screening for haemoglobin and fasting glucose levels. The positive effects are attributable to standardization of care processes, which is consistent with previous studies of clinical pathways [11, 20, 21] . Despite the significant improvement in risk screening assessments and preventive strategies, implementation levels of 80-90% were not reached. This can be attributed to the referral rate to the pathway of 61%. Because 2015 was the first year of implementation, the Evidence-based guidelines recommend an osteoporotic risk assessment with a BMD measurement and calcium and vitamin D supplements or adequate intake as a prevention strategy [5, 7] ; however, previous studies have shown that patients rarely undergo a risk assessment [9, 22, 23] . Before pathway implementation, only 10% of patients received a risk assessment, despite its being recommended for all patients (compared with 58% after pathway implementation). At PCa diagnosis, in previous studies 25-40% of patients with PCa receiving ADT had osteoporosis [24] , which is not surprising given that the average age of these patients is 65 years. This is consistent with the present study, in which 41% of the patients undergoing screening had a risk profile. Additionally, patients receiving ADT have an increased risk of fracture [25, 26] . After implementation of the pathway, osteoporosis All blood values were measured <3 months after start of ADT. ADT, androgen deprivation therapy; BMD, bone mineral density.
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More than half of the patients had hypertension at baseline and 19% had diabetes, which are rates similar to those observed in the study by Cheung et al. [21] (61% and 25%, respectively). At baseline, 73% patients were overweight or obese, which is similar to the general age-adjusted male population in Western Europe (77%) [27] . One of the side effects of ADT is the increase in fat mass and the development of metabolic syndrome [5, 7] . At onset of ADT, the majority of patients already have a diagnosis of overweight, therefore, proper diet counselling is indicated [28] , but was rarely given as standard practice before pathway implementation. In addition to the positive effects of a diet intervention on cardiometabolic health, it can also support bone health [29] . After pathway implementation, the referral rate to a dietician increased to 58%, and 64% of these patients followed the advice. Because of the comorbidities at baseline and the higher risk of cardiometabolic complications of ADT [5, 7] , proper screening at onset of ADT and during treatment is indicated [7, 21] ; however, before pathway implementation, both metabolic and cardiac risk screenings were rarely documented (4% and 16%, respectively). These rates are lower than those observed in our previous European study [9] , in which 25% of participants reported that a metabolic risk assessment was performed. This discrepancy can be explained by the difference in research method (intention was recorded in the previous study vs actual performance in the present study). These results suggest that a clinical pathway can serve as a method to standardize these screening strategies and increase uptake.
Exercise is an evidence-based treatment strategy for several ADT-induced side effects, such as fatigue, and cardiometabolic and bone complications [7, 30, 31] . Studies have shown that only a minority of patients with PCa perform sufficient physical activity according to exercise guidelines for such patients [32, 33] ; therefore, the clinical pathway incorporated a supervised exercise programme. Meeting the physical activity recommendation and/or referral to a supervised exercise programme increased significantly to 62% after pathway implementation. This uptake was attributable to the tackling of previously described barriers by the clinical pathway, such as resources, lack of time to promote exercise or referral and education about exercise [9, 34, 35] . Despite the positive evolution, there is still much room for improvement. After referral and/or recommendation, 37% of the patients did not follow the exercise advice. Interventions are necessary to increase further uptake of exercise advice and to address other possible barriers.
A variety of psychological changes are also influenced by ADT, such as emotional liability, depression and sense of masculinity loss [6, 36, 37] . Psycho-education can act on these problems [37, 38] and exercise may also have a positive impact [37] . After implementation of the pathway, a significant increase in referral to a psychologist was observed. Of those who received a referral, one out of three went to one or more psychological counselling session(s) and/or interactive psychosocial group session(s). By considering psychological counselling as standard care through the introduction of a clinical pathway, the threshold and existing taboo with regard to physiological counselling can be addressed.
Undergoing ADT can negatively influence haemoglobin levels [5, 7, 21] . Mild anaemia is a common side effect which has no major clinical impact [5, 36] , but moderate anaemia can have a negative impact on fatigue [36] . The clinical pathway did not show a significant impact on haemoglobin screening because screening before pathway implementation was already high as this is commonly requested in standard blood controls.
The present study has several limitations. The pathway was only implemented in one hospital, therefore, we could not correct for contextual factors. Future studies should incorporate different hospitals. A clinical pathway is a complex intervention, thus the active component of the intervention is difficult to specify [11] . Future research should examine the critical components of success of a clinical pathway (e.g. the role of the presence of pathway facilitator/coordinator). Additionally, there are some limitations and biases inherent to retrospective methods. Data depended on electronic health records, which included physicians' and other healthcare givers' notes. Further standardization of medical health records is therefore indicated and future prospective studies are necessary. Additionally, during comparison between groups (control vs intervention group), a time bias could occur because of an increased awareness of the recommended guidelines and strategies over time; however, we anticipate that the bias effect would have been quite low because of the short time frame of 1 year between groups. We believe that the increase in application of prevention strategies after pathway implementation outweigh the possible elevation caused by increasing awareness over a 1-year time period.
Despite these limitations, the study has several unique features. This study assessed a possible method (e.g. a clinical pathway) to increase implementation of evidencebased guidelines to manage ADT-induced side effects (risk screening assessments, preventive strategies with lifestyle advice, and an exercise programme). The next step is to examine the possible utility of the pathway method with regard to long-term implementation strategies. Additionally, a relatively large sample of patients with PCa was screened in a systematic approach for eligibility and data extraction. Our findings show that a clinical pathway for patients with PCa improved the implementation of evidence-based strategies for ADT-induced side effects and therefore improved quality of care. A clinical pathway may be one of the solutions to bridge the gap between evidence-based guidelines and daily clinical practice.
